Gilead Sciences has reported full-year 2025 revenue of USD 29.4 billion, a 2% year-on-year increase, with product revenue reaching USD 28.9 billion. Excluding the COVID-19 therapy Veklury, product revenue grew by 4%. The company's HIV franchise, which accounts for over 70% of total revenue, generated USD 20.8 billion, a 6% increase, led by the blockbuster drug Biktarvy (USD 14.3 billion). The launch of the twice-yearly injectable HIV prevention therapy, Yeztugo, further strengthened the HIV portfolio. The liver disease business grew 6% to USD 3.2 billion, primarily driven by the rapid uptake of Livdelzi, which has captured over 50% of the US second-line primary biliary cirrhosis (PBC) treatment market.

The oncology segment generated USD 3.2 billion, a 2% decline, as CAR-T therapies faced increased competition. However, the ADC drug Trodelvy (sacituzumab govitecan) grew 6% to USD 1.4 billion.

Gilead expects a number of key milestones in 2026, including potential regulatory submissions and approvals for the BCMA CAR-T therapy anitocabtagene autoleucel and a new HIV combination. The company forecasts 2026 product sales in the range of USD 29.6 billion to USD 30.0 billion, supported by a pipeline of over 120 programs, including 29 Phase III studies.

PharmCube's NextBiopharm® database shows that the announcement positioned anitocabtagene autoleucel as the most advanced clinical-stage BRCA CAR-T, although it faces four approved products by BMS, J&J, GC Cell and Huadong Medicine. Click here to request a free trial for NextBiopharm®.